An open pilot study of nefazodone in depression with anger attacks: Relationship between clinical response and receptor binding

Psychiatry Research - Neuroimaging

Volumn 116, Issue 3, 2002, Pages 151-161

  Mischoulon, David ^a   Dougherty, Darin D ^a   Bottonari, Kathryn A ^a   Gresham, Robert L ^a   Sonawalla, Shamsah B ^a   Fischman, Alan J ^a   Fava, Maurizio ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antidepressant; Dopamine; Neuroimaging; Positron emission tomography (PET); Receptor; Serotonin

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE C 11; NEFAZODONE; SETOPERONE F 18; TRACER; UNCLASSIFIED DRUG; ANTIDEPRESSANT AGENT; DOPAMINE RECEPTOR; SEROTONIN RECEPTOR; TRIAZOLE DERIVATIVE;

ADULT; ANGER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HAMILTON SCALE; HUMAN; INTERVIEW; MAJOR DEPRESSION; MALE; OPEN STUDY; OUTPATIENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; QUESTIONNAIRE; RATING SCALE; RECEPTOR BINDING; STATISTICAL SIGNIFICANCE; BINDING SITE; BRAIN; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DEPRESSION; HOSPITALIZATION; METABOLISM; PILOT STUDY; THALAMUS;

ADULT; ANGER; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BINDING SITES; BRAIN; DEPRESSION; FEMALE; HUMANS; MALE; PILOT PROJECTS; QUESTIONNAIRES; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; SEVERITY OF ILLNESS INDEX; THALAMUS; TOMOGRAPHY, EMISSION-COMPUTED; TRIAZOLES;

EID: 1842855803     PISSN: 09254927     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0925-4927(02)00082-3     Document Type: Article

References (49)

1. 11C]-5-hydroxytryptophan in major depression: a positron emission tomography study on patients and healthy volunteers. Acta Psychiatrica Scandinavica. 83:1991;449-455.
2. 11C]-L-DOPA in healthy volunteers and patients with unipolar major depression. Depression. 1:1993;71-81.
3. Armitage R., Rush A.J., Trivedi M., Cain J., Roffwarg H.P. The effects of nefazodone on sleep architecture in depression. Neuropsychopharmacology. 10:1994;123-127.
4. Armitage R., Yonkers K., Cole D., Rush A.J. A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients. Journal of Clinical Psychopharmacology. 17:1997;161-168.
5. 18F]-setoperone during depressive illness and antidepressant treatment with clomipramine. Biological Psychiatry. 45:1999;180-186.
6. Baldwin D.S., Hawley C.J., Abed R.T., Maragakis B.P., Cox J., Buckingham S.A., Pover G.H., Ascher A. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. Journal of Clinical Psychiatry. 57:(Suppl. 2):1996;46-52.
7. Biver F., Wikler D., Lotstra F., Damhaut P., Goldman S., Mendlewicz J. Serotonin 5-HT2 receptor imaging in major depression: focal changes in orbito-insular cortex. British Journal of Psychiatry. 171:1997;444-448.
8. Boerner R.J., Möller H.J. The importance of new antidepressants in the treatment of anxiety/depressive disorders. Pharmacopsychiatry. 32:1999;119-126.
9. Bystritsky A., Rosen R., Suri R., Vapnik T. Pilot open-label study of nefazodone in panic disorder. Depression and Anxiety. 10:1999;137-139.
10. Coccaro E.F., Siever L.J., Klar H.M., Maurer G., Cochrane K., Cooper T.B., Mohs R.C., Davis K.H. Serotonergic studies in patients with affective and personality disorders: correlates with suicidal and impulsive aggressive behavior. Archives of General Psychiatry. 46:1989;587-599.
11. D'haenen H., Bossuyt A., Mertens J., Bossuyt-Piron C., Gijsemans K., Kaufman L. SPECT imaging of serotonin 2 receptors in depression. Psychiatry Research: Neuroimaging. 45:1992;227-237.
12. Davis R., Whittington R., Bryson H.M. Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs. 53:1997;608-636.
13. Fava M., Alpert J., Nierenberg A.A., Ghaemi N., O'Sullivan R., Tedlow J., Worthington J., Rosenbaum J. Fluoxetine treatment of anger attacks: a replication study. Annals of Clinical Psychiatry. 8:1996;7-10.
14. Fava M., Anderson K., Rosenbaum J.F. 'Anger attacks': possible variants of panic and major depressive disorders. American Journal of Psychiatry. 147:1990;867-870.
15. Fava M., Nierenberg A.A., Quitkin F.M., Zisook S., Pearlstein T., Stone A., Rosenbaum J. A preliminary study on the efficacy of sertraline and imipramine on anger attacks in atypical depression and dysthymia. Psychopharmacology Bulletin. 33:1997;101-103.
16. Fava M., Rosenbaum J.F., McCarthy M., Pava J., Steingard R., Bless E. Anger attacks in depressed outpatients and their response to fluoxetine. Psychopharmacology Bulletin. 27:1991;275-279.
17. Fava M., Rosenbaum J.F., Pava J.A., McCarthy M.K., Steingard R.J., Bouffides E. Anger attacks in unipolar depression. Part I: clinical correlates and response to fluoxetine treatment. American Journal of Psychiatry. 150:1993;1158-1163.
18. Fava M., Rosenbaum J.F. Anger attacks in depression. Depression and Anxiety. 6:1997;1-5.
19. Fava M., Vuolo R.D., Wright E.C., Nierenberg A.A., Alpert J.E., Rosenbaum J.F. Fenfluramine challenge in unipolar depression with and without anger attacks. Psychiatry Research. 94:2000;9-18.
20. Fava M. Weight gain and antidepressants. Journal of Clinical Psychiatry. 61:(Suppl. 11):2000;37-41.
21. Fawcett J., Marcus R.N., Anton S.F., O'Brien K., Schwiderski U. Response of anxiety and agitation symptoms during nefazodone treatment of major depression. Journal of Clinical Psychiatry. 56:(Suppl. 6):1995;37-42.
22. Feiger A., Kiev A., Shrivastava R.K., Wisselink P.G., Wilcox C.S. Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. Journal of Clinical Psychiatry. 57:(Suppl. 2):1996;53-62.
23. Feighner J.P. Overview of antidepressants currently used to treat anxiety disorders. Journal of Clinical Psychiatry. 60:(Suppl. 22):1999;18-22.
24. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for Axis I DSM-IV Disorders - Patient Edition (With Psychotic Screen), Version 2.0. 1995;Biometrics Research Department, New York State Psychiatric Institute, New York, NY.
25. Gillin J.C., Rapaport M., Erman M.K., Winokur A., Albala B.J. A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial. Journal of Clinical Psychiatry. 58:1997;185-192.
26. Gunn R.N., Lammertsma A.A., Hume S.P., Cunningham V.J. Parametric imaging of ligand-receptor interaction using a reference tissue model. NeuroImage. 6:1997;279-287.
27. Guy, W. (Ed.), 1976. ECDEU Assessment Manual for Psychopharmacology, revised. DHEW Publication No (ADM) 76-338, National Institute of Mental Health, Rockville, MD.
28. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry. 23:1960;56-62.
29. Hertzberg M.A., Feldman M.E., Beckham J.C., Moore S.D., Davidson J.R. Open trial of nefazodone for combat-related post-traumatic stress disorder. Journal of Clinical Psychiatry. 59:1998;460-464.
30. Hirschfeld R.M. Care of the sexually active depressed patient. Journal of Clinical Psychiatry. 60:(Suppl. 17):1999;32-35.
31. Kellner R. A symptom questionnaire. Journal of Clinical Psychiatry. 48:1987;268-274.
32. 123I]-IBZM SPECT. Psychiatry Research: Neuroimaging. 90:1999;91-101.
33. Kuzel R.J. Treating comorbid depression and anxiety. Journal of Family Practice. 43:(Suppl. 6):1996;S45-53.
34. Laasonen-Balk T., Kuikka J., Viinamaki H., Husso-Saastamoinen M., Lehtonen J., Tiihonen J. Striatal dopamine transporter density in major depression. Psychopharmacology (Berlin). 144:1999;282-285.
35. Martinot M., Bragulat V., Artiges E., Dolle F., Hinnen F., Jouvent R., Martinot J. Decreased presynaptic dopamine function in the left caudate of depressed patients with affective flattening and psychomotor retardation. American Journal of Psychiatry. 158:2001;314-316.
36. Mayberg H.S. Limbic-cortical dysregulation: a proposed model of depression. Journal of Neuropsychiatry and Clinical Neuroscience. 9:1997;471-481.
37. Meltzer C.C., Price J.C., Mathis C.A., Greer P.J., Cantwell M.N., Houck P.R., Mulsant B.H., Ben-Eliezer D., Lopresti B., DeKosky S.T., Reynolds C.F. III. PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders. American Journal of Psychiatry. 156:1999;1871-1878.
38. 18F]-setoperone PET. Psychopharmacology (Berlin). 144:1999;279-281.
39. Otto M.W. Statistical methods for clinical psychopharmacology trials. Fava M., Rosenbaum J. Research Designs and Methods in Psychiatry. 1992;247-266 Elsevier Science Publishers, Amsterdam.
40. Reynolds R.D. Sertraline-induced anorgasmia treated with intermittent nefazodone (letter). Journal of Clinical Psychiatry. 58:1997;89.
41. Robinson D.S., Roberts D.L., Smith J.M., Stringfellow J.C., Kaplita S.B., Seminara J.A., Marcus R.N. The safety profile of nefazodone. Journal of Clinical Psychiatry. 57:(Suppl. 2):1996;31-38.
42. Rush A.J., Armitage R., Gillin J.C., Yonkers K.A., Winokur A., Moldofsky H., Vogel G.W., Kaplita S.B., Fleming J.B., Montplaisir J., Erman M.K., Albala B.J., McQuade R.D. Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. Biological Psychiatry. 44:1998;3-14.
43. Scharf M.B., McDannold M., Zaretsky N., Spinner O., Stover R., Berkowitz D.V., Conrad C. Evaluation of sleep architecture and cyclic alternating pattern rates in depressed insomniac patients treated with nefazodone hydrochloride. American Journal of Therapeutics. 6:1999;77-82.
44. Sharpley A.L., Williamson D.J., Attenburrow M.E., Pearson G., Sargent P., Cowen P.J. The effects of paroxetine and nefazodone on sleep: a placebo controlled trial. Psychopharmacology (Berlin). 126:1996;50-54.
45. Stewart D.E. Hepatic adverse reactions associated with nefazodone. Canadian Journal of Psychiatry. 47:2002;375-377.
46. Thase M.E. Antidepressant treatment of the depressed patient with insomnia. Journal of Clinical Psychiatry. 60:(Suppl. 17):1999;28-31.
47. Vogal G., Cohen J., Mullis D., Kensler T., Kaplita S. Nefazodone and REM sleep: how do antidepressant drugs decrease REM sleep? Sleep. 21:1998;70-77.
48. Yatham L.N., Liddle P.F., Dennie J., Shiah I.S., Adam M.J., Lane C.J., Lam R.W., Ruth T.J. Decrease in brain serotonin 2 receptor binding in patients with major depression following desipramine treatment: a positron emission tomography study with fluorine-18-labeled setoperone. Archives of General Psychiatry. 56:1999;705-711.
49. Yudofsky S.C., Silver J.M., Jackson W., Endicott J., Williams D. The Overt Aggression Scale for the objective rating of verbal and physical aggression. American Journal of Psychiatry. 143:1986;35-39.